LONDON, Oct 8 (Reuters) - A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company’s home market.
Tag Archives: British
How Cannabis-based Drugmaker GW Finally Cracked America
When a pair of British doctors set out to make medicines from the cannabis plant 16 years ago, they knew it would take some time to crack the world’s biggest pharmaceuticals market.